SuperGen, Inc. is a pharmaceutical company engaged primarily to the discovery and development of therapies to treat patients with cancer. The Company acquires products developed by other companies and applies additional developmental effort to expand sales or advance these products clinically towards approval for marketing. The Company’s primary developmental efforts revolve around the products progressing out of its acquisition of Montigen Pharmaceuticals, Inc. (Montigen), a small-molecule drug discovery company. The Company initiated Phase I in-human clinical trials and Phase Ib clinical trials for the first Montigen product, MP-470, a deoxyribonucleic acid (DNA) repair suppressor. In November 2008, the Company received clearance to proceed with clinical trials for a second internally developed product, SGI-1776, a PIM kinase inhibitor.